46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04909931 (ClinicalTrials.gov) | June 15, 2021 | 11/5/2021 | Vitamin D Supplementation on Outcome and Disease Activity. | Vitamin D Supplementation on Outcome and Disease Activity in Rheumatoid Arthritis Patients at Rajavithi Hospital : A Randomized Clinical Trial | Rheumatoid Arthritis, Vitamin D , Disease Activity, DAS28ESR | Drug: Vitamin D 2;Drug: Placebo | Rajavithi Hospital | NULL | Recruiting | 18 Years | N/A | All | 60 | N/A | Thailand |
| 2 | NCT05078502 (ClinicalTrials.gov) | June 1, 2021 | 4/10/2021 | Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs(csDMARD) in Rheumatoid Arthritis Patients | Role of Vitamin D3 Supplementation With Conventional Synthetic Disease Modifying Antirheumatic Drugs (csDMARD) in Rheumatoid Arthritis Patients: Randomized Double-blind Placebo Controlled Trial | Rheumatoid Arthritis | Dietary Supplement: Vitamin D3 | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | NULL | Completed | 18 Years | 70 Years | All | 58 | N/A | Bangladesh |
| 3 | NCT04472481 (ClinicalTrials.gov) | September 6, 2019 | 7/7/2020 | Vitamin D Effect in Rheumatoid Arthritis. | Vitamin D: Does It Help Tregs in Active Rheumatoid Arthritis Patients. | Active Rheumatoid Arthritis | Drug: Ergocalciferol 1.25 mg tablet | Tanta University | NULL | Completed | 33 Years | 60 Years | All | 20 | Phase 4 | Egypt |
| 4 | NCT04344405 (ClinicalTrials.gov) | June 1, 2019 | 9/4/2020 | Vitamin D as a Key Player in Rheumatoid Arthritis | Vitamin D as a Key Player in Rheumatoid Arthritis Immune Response | the Immunomodulatory Effect | Drug: Vitamin D;Drug: Steroid Drug | Assiut University | NULL | Completed | 20 Years | 70 Years | All | 40 | Phase 3 | Egypt |
| 5 | JPRN-UMIN000030828 | 2018/01/15 | 15/01/2018 | The preventive effect for new vertebral fractures of zoledronic acid and denosumab combined with vitamin D in patients with rheumatoid arthritis. | Rheumatoid ArthritisOsteoporosis | zoledronic acid denosumab | Osaka City University Graduate School of Medicine | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 500 | Not selected | Japan | |
| 6 | JPRN-UMIN000022364 | 2016/05/10 | 20/05/2016 | Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis | Treatment strategy of minodronate in osteoporotic patients with rheumatoid arthritis - Effectiveness of minodronate in osteoporotic patients with rheumatoid arthritis | Osteoprotic patients with rheumatoid arthritis | The selection criteria is based on which treatment each patient wants to take Minodronate group: oral intake 50mg per month Minodronate plus active vitamin D group: oral intake 50mg minodronate per month and eldecalcitol 0.75ug per day after breakfast | Department of Orthopaedic Surgery Shinshu University School of Medicine | NULL | Complete: follow-up complete | 50years-old | 100years-old | Male and Female | 140 | Not applicable | Japan |
| 7 | NCT02944799 (ClinicalTrials.gov) | December 2015 | 27/6/2016 | Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis | Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass | Rheumatoid Arthritis;Osteoporosis | Drug: Placebo;Drug: Alendronate;Drug: Calcium;Drug: Vitamin D | University of Aarhus | NULL | Active, not recruiting | 18 Years | N/A | All | 69 | Phase 2 | Denmark |
| 8 | NCT02633332 (ClinicalTrials.gov) | February 2015 | 30/11/2015 | Use of Well Known Drugs for New Destination - RA Improvement (RANT) | Observational Retrospective Study About the Use of Well Known Drugs in Combination to Obtain a New Drug to Improve Quality of Life/Health in Patient With Diagnosed Rheumatoid Arthritis Not Responding to Commonly Used Treatments | Rheumatoid Arthritis;Autoimmune Diseases;Disorder of Synovium;Sjogren's Syndrome;Acute and Chronic Inflammation;Disorder of Pleura and Pleural Cavity;Felty's Syndrome;Rheumatoid Nodules | Drug: Vitamin D3;Drug: Lipitor®;Drug: Acycloguanosine;Drug: Tetracycline;Drug: methotrexate;Drug: etanercept | Università Popolare Homo & Natura | NULL | Completed | 18 Years | 75 Years | Both | 15 | Phase 1 | Italy |
| 9 | JPRN-UMIN000014737 | 2014/08/01 | 01/08/2014 | The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity. | rheumatoid arthritis | Denosumab group: Denosumab 60mg is administered by subcutaneous injections every 6 months (at baseline, at 6 months and at 12 months). All patients are to take vitamin D. BP group: Patients take BP continuously. All patients are to take vitamin D. | Yokohama City University Medical Center | NULL | Complete: follow-up complete | 50years-old | 90years-old | Male and Female | 286 | Not selected | Japan | |
| 10 | NCT02243800 (ClinicalTrials.gov) | November 2011 | 16/9/2014 | Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency | Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency | Rheumatoid Arthritis;Vitamin D Deficiency | Other: cholecalciferol versus placebo | University Hospital, Clermont-Ferrand | CRINEX Laboratory;BP 337 - 3 rue de Gentilly;92541 MONTROUGE Cedex FRANCE | Recruiting | 18 Years | N/A | Both | 164 | Phase 3 | France |
| 11 | NCT01400516 (ClinicalTrials.gov) | August 2011 | 21/7/2011 | Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial | Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial | Rheumatoid Arthritis | Drug: Teriparatide;Drug: calcium citrate;Drug: Vitamin D;Drug: TNF antagonist | Brigham and Women's Hospital | Eli Lilly and Company | Completed | 45 Years | N/A | All | 26 | Phase 4 | United States |
| 12 | EUCTR2009-012615-18-FR (EUCTR) | 16/02/2011 | 05/11/2010 | Efficacy and safety of cholecalciferol on rheumatoid arthritis activity in patients with vitamin D deficiency - SCORPION | Efficacy and safety of cholecalciferol on rheumatoid arthritis activity in patients with vitamin D deficiency - SCORPION | Rheumatoid arthritis (RA) MedDRA version: 12.1;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions | Trade Name: UVEDOSE INN or Proposed INN: COLECALCIFEROL | CHU de Clermont-Ferrand | NULL | Not Recruiting | Female: yes Male: yes | France | ||||
| 13 | NCT01351805 (ClinicalTrials.gov) | January 2011 | 4/5/2011 | Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain | Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain | Autoimmune Diseases;Systemic Inflammatory Process;Knee Pain Chronic;Osteoarthritis;Rheumatoid Arthritis | Drug: Fish Oil;Dietary Supplement: Vitamin D;Other: placebo pill | Brigham and Women's Hospital | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Active, not recruiting | 50 Years | N/A | All | 25876 | N/A | United States |
| 14 | EUCTR2009-015835-34-IT (EUCTR) | 09/04/2010 | 29/03/2010 | VITAMIN D EFFECT ON T LYMPHOCYTES AND OSTEOCLASTOGENESIS IN RHEUMAOID ARTHRITIS - ND | VITAMIN D EFFECT ON T LYMPHOCYTES AND OSTEOCLASTOGENESIS IN RHEUMAOID ARTHRITIS - ND | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10003268;Term: Arthritis rheumatoid | Trade Name: DIBASE*IM OS 2F 1ML 300000UI/M INN or Proposed INN: Colecalciferol | AZIENDA OSPEDALIERA ORDINE MAURIZIANO | NULL | Not Recruiting | Female: yes Male: no | Phase 3 | Italy | |||
| 15 | NCT00279461 (ClinicalTrials.gov) | May 2009 | 17/1/2006 | Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis | Vitamin D Deficiency Causes Immune Dysfunction and Enables or Perpetuates the Development of Rheumatoid Arthritis: Clinical Trial and Investigations on Dendritic Cells | Arthritis, Rheumatoid;Vitamin D Deficiency | Drug: Placebo in arm A and Vitamin D in arm B;Drug: vitamin D 3 for arm A ,and matching placebo for arm B | Indiana University | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 2 | United States |
| 16 | NCT01426347 (ClinicalTrials.gov) | January 2009 | 29/8/2011 | Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis | Vitamin Therapy in Rheumatoid Arthritis | Rheumatoid Arthritis;Vitamin D Deficiency | Drug: Placebo sugar pill;Drug: Ergocalciferol | Johns Hopkins University | NULL | Completed | 18 Years | 75 Years | All | 139 | N/A | United States |
| 17 | NCT00427804 (ClinicalTrials.gov) | January 2007 | 25/1/2007 | Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption | Tumor Necrosis Factor-a Induces Vitamin D Resistance in Small Intestinal Calcium Absorption | Rheumatoid Arthritis;Crohn's Disease | Drug: calcitriol | Atlanta VA Medical Center | Emory University | Completed | 18 Years | 50 Years | Male | 9 | N/A | United States |
| 18 | NCT00423358 (ClinicalTrials.gov) | February 2005 | 17/1/2007 | Treatment of Hypovitaminosis D in Rheumatoid Arthritis | Treatment of Hypovitaminosis D in Rheumatoid Arthritis | Rheumatoid Arthritis;Hypovitaminosis D | Dietary Supplement: Vitamin D;Dietary Supplement: placebo | University of Wisconsin, Madison | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | 18 Years | 90 Years | All | 22 | N/A | United States |
| 19 | NCT00138983 (ClinicalTrials.gov) | May 2000 | 29/8/2005 | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. | Prevention of Glucocorticoid-Induced Osteoporosis in Patients With Rheumatic Diseases. The STOP-Study: a Randomized Placebo Controlled Trial With Alendronate Versus Alfacalcidol. | Rheumatoid Arthritis;Polymyalgia Rheumatica;Giant Cell Arteritis;Polymyositis;Wegener’s Granulomatosis | Drug: Alendronate versus alfacalcidol (1-alpha OH vitamin D) | UMC Utrecht | Dutch Health Care Insurance Board | Completed | 18 Years | 90 Years | Both | 200 | Phase 3 | Netherlands |
| 20 | NCT02932644 (ClinicalTrials.gov) | October 1999 | 12/10/2016 | Vitamin D and Cardiovascular Events in Rheumatoid Arthritis | Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes. | Rheumatoid Arthritis;Cardiovascular Disease | Other: Baseline serum vitamin D level below 50 nmol/l;Other: Baseline serum vitamin D level at or above 50 nmol/l | Odense University Hospital | The Danish Rheumatism Association;University of Southern Denmark;Region of Southern Denmark;Pfizer;Odense Patient Explorative data Network (OPEN);The Danish Rheumatism Association;University of Southern Denmark;Region of Southern Denmark;Pfizer;Odense Patient Explorative data Network (OPEN) | Completed | 18 Years | 75 Years | Both | 160 | N/A | NULL |
| 21 | NCT00570934 (ClinicalTrials.gov) | March 1995 | 7/12/2007 | Supplementation With Vitamin D, Calcium or Both on Calcium Absorption and Bone Mineral Content in Children With JRA | Effect of Supplementation With 2000 International Units (IU) Vitamin D, 1gm Calcium or Both on Calcium Absorption and Bone Mineralization in Children With Juvenile Rheumatoid Arthritis | Juvenile Rheumatoid Arthritis | Dietary Supplement: Cholecalciferol;Dietary Supplement: Calcium;Dietary Supplement: Calcium and cholecalciferol;Drug: Placebo | University of Missouri-Columbia | NULL | Completed | 3 Years | 15 Years | Both | 24 | Phase 3 | United States |